Dylan R. Edwards

List of Publications by Year
in descending order

196 papers	21,621 citations	7096 78 h-index	9589 142 g-index
201 all docs	201 docs citations	201 times ranked	23756 citing authors

#	Article	IF	Citations
1	Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Cancers, 2021, 13, 1679.	3.7	4
2	ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis. Journal of Cell Science, 2020, 133, .	2.0	57
3	A novel stratification framework for predicting outcome in patients with prostate cancer. British Journal of Cancer, 2020, 122, 1467-1476.	6.4	9
4	Analysis of ADAMTS Effects on Cell Adhesion and Migration. Methods in Molecular Biology, 2020, 2043, 179-193.	0.9	2
5	ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells. Scientific Reports, 2019, 9, 12540.	3.3	18
6	HIF1Î± drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia. Oncogene, 2018, 37, 2676-2686.	5.9	25
7	DESNT: A Poor Prognosis Category of Human Prostate Cancer. European Urology Focus, 2018, 4, 842-850.	3.1	30
8	The Î²3â€integrin endothelial adhesome regulates microtubuleâ€dependent cell migration. EMBO Reports, 2018, 19, .	4.5	25
9	ADAMTS9, a member of the ADAMTS family, in Xenopus development. Gene Expression Patterns, 2018, 29, 72-81.	0.8	12
10	PI3KÎ´ and PI3KÎ³ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment. Blood Cancer Journal, 2017, 7, e539-e539.	6.2	22
11	Identification of novel peptide motifs in the serpin maspin that affect vascular smooth muscle cell function. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 336-344.	4.1	3
12	Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood, 2017, 129, 1320-1332.	1.4	226
13	NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood, 2017, 130, 1649-1660.	1.4	242
14	Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Research, 2017, 19, 33.	5.0	29
15	Systemic Ablation of MMP-9 Triggers Invasive Growth and Metastasis of Pancreatic Cancer via Deregulation of IL6 Expression in the Bone Marrow. Molecular Cancer Research, 2016, 14, 1147-1158.	3.4	44
16	Proteases in cancer drug delivery. Advanced Drug Delivery Reviews, 2016, 97, 144-155.	13.7	93
17	Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients. European Urology, 2016, 69, 229-230.	1.9	2
18	Bone Marrow Mesenchymal Stromal Cells Transfer Their Mitochondria to Acute Myeloid Leukaemia Blasts to Support Their Proliferation and Survival. Blood, 2016, 128, 772-772.	1.4	2

#	Article	IF	Citations
19	Metalloproteinaseâ€dependent and â€independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifsâ€15. International Journal of Cancer, 2015, 136, E14-26.	5.1	46
20	The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biology, 2015, 16, 113.	8.8	471
21	Suppressing Î²3-integrin triggers a neuropilin-1 dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. DMM Disease Models and Mechanisms, 2015, 8, 1105-19.	2.4	23
22	Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. Breast Cancer Research, 2015, 17, 38.	5.0	35
23	Acute Depletion of Endothelial Î²3-Integrin Transiently Inhibits Tumor Growth and Angiogenesis in Mice. Circulation Research, 2014, 114, 79-91.	4.5	36
24	Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of Î±vÎ²6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence. Clinical Cancer Research, 2014, 20, 344-357.	7.0	77
25	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
26	Matrix metalloproteinases: a dual role in breast cancer?. Breast Cancer Management, 2013, 2, 353-356.	0.2	1
27	Matrix Metalloproteinase 8 (Collagenase 2) Induces the Expression of Interleukins 6 and 8 in Breast Cancer Cells. Journal of Biological Chemistry, 2013, 288, 16282-16294.	3.4	52
28	Intradermal air pouch leukocytosis as an in vivo test for nanoparticles. International Journal of Nanomedicine, 2013, 8, 4745.	6.7	42
29	TGF-Î²-Elicited Induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 Expression in Fibroblasts Involves Complex Interplay between Smad3, p38Î±, and ERK1/2. PLoS ONE, 2013, 8, e57474.	2.5	55
30	Genome-Wide Responses of Female Fruit Flies Subjected to Divergent Mating Regimes. PLoS ONE, 2013, 8, e68136.	2.5	7
31	Insights into the Mechanism of Quantum Dot-Sensitized Singlet Oxygen Production for Photodynamic Therapy. Journal of Physical Chemistry C, 2012, 116, 9334-9342.	3.1	65
32	mRNA profiling of the cancer degradome in oesophagoâ€“gastric adenocarcinoma. British Journal of Cancer, 2012, 107, 143-149.	6.4	17
33	MMP2 Activity is Critical for TGFÎ²2-Induced Matrix Contractionâ€”Implications for Fibrosis. , 2012, 53, 4085.		51
34	Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates. Photochemical and Photobiological Sciences, 2011, 10, 822-831.	2.9	295
35	New insights into the plasticity of the endothelial phenotype. Biochemical Society Transactions, 2011, 39, 1639-1643.	3.4	8
36	Evaluation of effects caused by differentially spliced Ets-1 transcripts in fibroblasts. International Journal of Oncology, 2011, 39, 1073-82.	3.3	1

#	Article	IF	Citations
37	The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Frontiers in Bioscience - Landmark, 2011, 16, 1861.	3.0	83
38	ERK5 signalling in prostate cancer promotes an invasive phenotype. British Journal of Cancer, 2011, 104, 664-672.	6.4	90
39	Matrix metalloproteinases: protective roles in cancer. Journal of Cellular and Molecular Medicine, 2011, 15, 1254-1265.	3.6	160
40	MMP-1 drives immunopathology in human tuberculosis and transgenic mice. Journal of Clinical Investigation, 2011, 121, 1827-1833.	8.2	197
41	ADAMs and protein disulfide isomerase: the key to regulated cell-surface protein ectodomain shedding?. Biochemical Journal, 2010, 428, e3-e5.	3.7	14
42	Avoiding spam in the proteolytic internet: Future strategies for anti-metastatic MMP inhibition. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 95-102.	4.1	65
43	Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2010, 16, 2022-2035.	7.0	100
44	Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases. Cancer Research, 2010, 70, 6902-6912.	0.9	49
45	G-helix of Maspin Mediates Effects on Cell Migration and Adhesion. Journal of Biological Chemistry, 2010, 285, 36285-36292.	3.4	34
46	Reversible transdifferentiation of blood vascular endothelial cells to a lymphatic-like phenotype in vitro. Journal of Cell Science, 2010, 123, 3808-3816.	2.0	44
47	Mycobacterium tuberculosis Upregulates Microglial Matrix Metalloproteinase-1 and -3 Expression and Secretion via NF-Î¹Bâ€“ and Activator Protein-1â€“Dependent Monocyte Networks. Journal of Immunology, 2010, 184, 6492-6503.	0.8	70
48	Real-Time PCR Expression Profiling of MMPs and TIMPs. Methods in Molecular Biology, 2010, 622, 159-173.	0.9	9
49	HDAC-mediated control of ERK- and PI3K-dependent TGF-Î²-induced extracellular matrix-regulating genes. Matrix Biology, 2010, 29, 602-612.	3.6	74
50	The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. Cancer Letters, 2010, 290, 114-122.	7.2	26
51	Reversible transdifferentiation of blood vascular endothelial cells to a lymphatic-like phenotype in vitro. Development (Cambridge), 2010, 137, e2208-e2208.	2.5	0
52	ADAM and ADAMTS gene expression in native and wound healing human lens epithelial cells. Molecular Vision, 2010, 16, 2765-76.	1.1	11
53	Src Stimulates Fibroblast Growth Factor Receptor-2 Shedding by an ADAM15 Splice Variant Linked to Breast Cancer. Cancer Research, 2009, 69, 4573-4576.	0.9	30
54	Cutting Edge: The Metalloproteinase ADAM17/TNF-Î±-Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein. Journal of Immunology, 2009, 182, 49-53.	0.8	130

#	Article	IF	Citations
55	TGF-Î²1 Limits Plaque Growth, Stabilizes Plaque Structure, and Prevents Aortic Dilation in Apolipoprotein E-Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1251-1257.	2.4	86
56	Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Research, 2009, 11, R24.	5.0	101
57	Brk Protects Breast Cancer Cells from Autophagic Cell Death Induced by Loss of Anchorage. American Journal of Pathology, 2009, 175, 1226-1234.	3.8	56
58	The role of acetylation in Timp-1 regulation. International Journal of Experimental Pathology, 2008, 85, A18-A19.	1.3	0
59	Expression profiling of metalloproteinases and inhibitors in cartilage. International Journal of Experimental Pathology, 2008, 85, A23-A23.	1.3	0
60	Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. British Journal of Cancer, 2008, 99, 126-132.	6.4	28
61	Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumourâ€“stroma interactions. BJU International, 2008, 101, 765-774.	2.5	20
62	The ADAM metalloproteinases. Molecular Aspects of Medicine, 2008, 29, 258-289.	6.4	955
63	Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synthesis for phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biology, 2008, 27, 128-138.	3.6	28
64	The regulation of matrix metalloproteinases and their inhibitors. International Journal of Biochemistry and Cell Biology, 2008, 40, 1362-1378.	2.8	474
65	Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma. Molecular Cancer Research, 2008, 6, 383-394.	3.4	60
66	Distinct Functionality of Tumor Cellâ€“Derived Gelatinases during Formation of Liver Metastases. Molecular Cancer Research, 2008, 6, 341-351.	3.4	22
67	Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion. Cancer Research, 2008, 68, 2755-2763.	0.9	172
68	Collagenase-2 Deficiency or Inhibition Impairs Experimental Autoimmune Encephalomyelitis in Mice. Journal of Biological Chemistry, 2008, 283, 9465-9474.	3.4	60
69	Matrix Metalloproteinase 13 Is Induced in Fibroblasts in Polyomavirus Middle T Antigen-Driven Mammary Carcinoma without Influencing Tumor Progression. PLoS ONE, 2008, 3, e2959.	2.5	28
70	Monocyte-Astrocyte Networks Regulate Matrix Metalloproteinase Gene Expression and Secretion in Central Nervous System Tuberculosis In Vitro and In Vivo. Journal of Immunology, 2007, 178, 1199-1207.	0.8	45
71	MMP and TIMP Expression in Quiescent, Dividing, and Differentiating Human Lens Cells. , 2007, 48, 4192.		23
72	Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling. Cancer Research, 2007, 67, 8615-8623.	0.9	133

#	Article	IF	Citations
73	Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. International Journal of Oncology, 2007, 30, 1263.	3.3	13
74	Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: Correlation of MMP-14 mRNA expression and proteolytic activity. European Journal of Cancer, 2007, 43, 1764-1771.	2.8	44
75	Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia, 2007, 55, 516-526.	4.9	87
76	TISSUE INHIBITOR OF METALLOPROTEINASE-3 IS UP-REGULATED BY TRANSFORMING GROWTH FACTOR-Î²1 IN VITRO AND EXPRESSED IN FIBROBLASTIC FOCI IN VIVO IN IDIOPATHIC PULMONARY FIBROSIS. Experimental Lung Research, 2006, 32, 201-214.	1.2	47
77	Research tissue banking in otolaryngology: organization, methods and uses, with reference to practical, ethical and legal issues. Journal of Laryngology and Otology, 2006, 120, 433-438.	0.8	3
78	Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. British Journal of Cancer, 2006, 94, 569-577.	6.4	71
79	MicroRNAs and the hallmarks of cancer. Oncogene, 2006, 25, 6170-6175.	5.9	344
80	Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendon. Arthritis and Rheumatism, 2006, 54, 832-842.	6.7	258
81	ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. International Journal of Cancer, 2006, 118, 1241-1247.	5.1	82
82	Tenascin-C Stimulates Glioma Cell Invasion through Matrix Metalloproteinase-12. Cancer Research, 2006, 66, 11771-11780.	0.9	127
83	Membrane-Type 4 Matrix Metalloproteinase Promotes Breast Cancer Growth and Metastases. Cancer Research, 2006, 66, 5165-5172.	0.9	61
84	The ADAMTS metalloproteinases. Biochemical Journal, 2005, 386, 15-27.	3.7	682
85	Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. British Journal of Cancer, 2005, 92, 2171-2180.	6.4	163
86	Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-Î²1 induced murine tissue inhibitor of metalloproteinases-1 gene expression. FEBS Journal, 2005, 272, 1912-1926.	4.7	28
87	Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology, 2005, 41, 857-867.	7.3	131
88	Metalloproteinases and their inhibitors in tumor angiogenesis. International Journal of Cancer, 2005, 115, 849-860.	5.1	251
89	Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovascular Research, 2005, 67, 39-49.	3.8	93
90	Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis, 2005, 26, 1233-1240.	2.8	41

#	Article	IF	Citations
91	Activation of Key Profibrotic Mechanisms in Transgenic Fibroblasts Expressing Kinase-deficient Type II Transforming Growth Factor-Î² Receptor (TÎ²RIIÎ”k). Journal of Biological Chemistry, 2005, 280, 16053-16065.	3.4	58
92	Mycobacterium tuberculosis, but Not Vaccine BCG, Specifically Upregulates Matrix Metalloproteinase-1. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1596-1604.	5.6	97
93	An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB Journal, 2005, 19, 1668-1670.	0.5	125
94	Combination of Tumor Necrosis Factor-Î± Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice. Circulation Research, 2005, 97, 380-390.	4.5	151
95	Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Research, 2005, 7, R503.	2.0	153
96	Key Metalloproteinases Are Expressed by Specific Cell Types in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2004, 173, 5209-5218.	0.8	126
97	Dysregulated Expression of Adamalysin-Thrombospondin Genes in Human Breast Carcinoma. Clinical Cancer Research, 2004, 10, 2429-2440.	7.0	272
98	TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges. Journal of Pathology, 2004, 202, 391-394.	4.5	19
99	Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis and Rheumatism, 2004, 50, 131-141.	6.7	379
100	Expression of metalloproteinases and inhibitors in the differentiation of P19CL6 cells into cardiac myocytes. Biochemical and Biophysical Research Communications, 2004, 322, 759-765.	2.1	43
101	Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Letters, 2004, 563, 129-134.	2.8	156
102	Diverse and potent activities of HGF/SF in skin wound repair. Journal of Pathology, 2004, 203, 831-838.	4.5	122
103	Extracellular matrix and matrix metalloproteinases in sciatic nerve. Journal of Neuroscience Research, 2003, 74, 417-429.	2.9	63
104	Expression profile of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in mature human odontoblasts and pulp tissue. European Journal of Oral Sciences, 2003, 111, 117-127.	1.5	143
105	Banking of fresh-frozen prostate tissue: methods, validation and use. BJU International, 2003, 91, 315-324.	2.5	35
106	TIMP-1 enhancer sequence â€“ real or bacterial?. British Journal of Cancer, 2003, 89, 1812-1812.	6.4	0
107	Insulin-like Growth Factor-II Regulates PTEN Expression in the Mammary Gland. Journal of Biological Chemistry, 2003, 278, 50422-50427.	3.4	56
108	Increase of Anti-Metastatic Efficacy by Selectivity- But Not Affinity-Optimization of Synthetic Serine Protease Inhibitors. Biological Chemistry, 2003, 384, 1515-25.	2.5	7

#	Article	IF	Citations
109	The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor-Î²1. Journal of Biological Chemistry, 2003, 278, 10304-10313.	3.4	211
110	Determinants of Human B Cell Migration Across Brain Endothelial Cells. Journal of Immunology, 2003, 170, 4497-4505.	0.8	175
111	Metalloproteinase Expression in PMA-stimulated THP-1 Cells. Journal of Biological Chemistry, 2003, 278, 51340-51346.	3.4	80
112	Metalloproteinases and their inhibitors in angiogenesis. Expert Reviews in Molecular Medicine, 2003, 5, 1-39.	3.9	101
113	Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain, 2003, 126, 2738-2749.	7.6	300
114	Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochemical Journal, 2003, 372, 799-809.	3.7	52
115	An Adverse Role for Matrix Metalloproteinase 12 after Spinal Cord Injury in Mice. Journal of Neuroscience, 2003, 23, 10107-10115.	3.6	181
116	Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Molecular Cancer Research, 2003, 1, 333-45.	3.4	131
117	Expression of Sorsby's Fundus Dystrophy Mutations in Human Retinal Pigment Epithelial Cells Reduces Matrix Metalloproteinase Inhibition and May Promote Angiogenesis. Journal of Biological Chemistry, 2002, 277, 13394-13400.	3.4	50
118	Phosphorylation-dependent Interactions between ADAM15 Cytoplasmic Domain and Src Family Protein-tyrosine Kinases. Journal of Biological Chemistry, 2002, 277, 4999-5007.	3.4	108
119	Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochemical Journal, 2002, 364, 89-99.	3.7	62
120	Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of Cell Science, 2002, 115, 3719-3727.	2.0	1,029
121	Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biology, 2002, 21, 75-88.	3.6	44
122	Proteases and Their Inhibitors in Gliomas. , 2002, , 241-268.		2
123	Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation, 2002, 70, 610-623.	1.9	73
124	The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukinâ€1 and oncostatin M: A timeâ€course study using realâ€time quantitative reverse transcriptionâ€“polymerase chain reaction. Arthritis and Rheumatism, 2002, 46, 961-967.	6.7	197
125	Quantitative Reverse Transcriptionâ€“Polymerase Chain Reaction (RT-PCR): A Comparison of Primer-Dropping, Competitive, and Real-Time RT-PCRs. Analytical Biochemistry, 2002, 300, 269-273.	2.4	57
126	Matrix metalloproteinases mediate the dismantling of mesenchymal structures in the tadpole tail during thyroid hormoneâ€induced tail resorption. Developmental Dynamics, 2002, 223, 402-413.	1.8	50

#	Article	IF	Citations
127	The role of chondrocyte senescence in osteoarthritis. Aging Cell, 2002, 1, 57-65.	6.7	349
128	Differential Expression of Matrix Metalloproteinases During Impaired Wound Healing of the Diabetes Mouse. Journal of Investigative Dermatology, 2002, 119, 91-98.	0.7	77
129	Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. British Journal of Pharmacology, 2002, 137, 1330-1338.	5.4	71
130	Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). Journal of Cell Science, 2002, 115, 3427-3438.	2.0	207
131	Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). Journal of Cell Science, 2002, 115, 3427-38.	2.0	166
132	Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Research, 2002, 62, 5543-50.	0.9	64
133	Expression of MMPs and TIMPs in Mammalian Cells. , 2001, 151, 181-189.		5
134	Monitoring MMP and TIMP mRNA Expression by RT-PCR. , 2001, 151, 305-320.		12
135	Perivascular Cells Regulate Endothelial Membrane Type-1 Matrix Metalloproteinase Activity. Biochemical and Biophysical Research Communications, 2001, 282, 463-473.	2.1	47
136	Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63ÂkDa active species. Biochemical Journal, 2001, 357, 107.	3.7	72
137	Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Journal of Clinical Pathology, 2001, 54, 275-280.	1.9	62
138	Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. British Journal of Cancer, 2001, 85, 55-63.	6.4	81
139	Metalloproteinases in biology and pathology of the nervous system. Nature Reviews Neuroscience, 2001, 2, 502-511.	10.2	946
140	Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-3 Are Key Regulators of Extracellular Matrix Degradation by Mouse Embryos1. Biology of Reproduction, 2001, 64, 1331-1337.	2.7	62
141	TIMP-1 Deficiency Does Not Attenuate Interstitial Fibrosis in Obstructive Nephropathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 736-748.	6.1	108
142	The Human Tissue Inhibitor of Metalloproteinases (TIMP)-1 Gene Contains Repressive Elements within the Promoter and Intron 1. Journal of Biological Chemistry, 2000, 275, 32664-32671.	3.4	34
143	Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-Oncology, 2000, 2, 145-150.	1.2	86
144	Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-Oncology, 2000, 2, 145-150.	1.2	9

#	Article	IF	Citations
145	Matrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes. Journal of Neuroscience, 1999, 19, 8464-8475.	3.6	255
146	Growth Factors and Cytokines Upregulate Gelatinase Expression in Bone Marrow CD34+ Cells and Their Transmigration Through Reconstituted Basement Membrane. Blood, 1999, 93, 3379-3390.	1.4	200
147	Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkinâ€™s Lymphomas. Blood, 1999, 94, 2080-2089.	1.4	195
148	Telomere-dependent senescence. Nature Biotechnology, 1999, 17, 313-313.	17.5	37
149	A Sequence-selective Single-strand DNA-binding Protein Regulates Basal Transcription of the Murine Tissue Inhibitor of Metalloproteinases-1 (Timp-1) Gene. Journal of Biological Chemistry, 1999, 274, 22197-22207.	3.4	22
150	Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials. Annals of the New York Academy of Sciences, 1999, 878, 236-270.	3.8	238
151	Elevated Plasma Gelatinase A (MMP-2) Activity Is Associated with Quiescent Crohn's Disease. Annals of the New York Academy of Sciences, 1999, 878, 578-580.	3.8	11
152	Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. British Journal of Haematology, 1999, 105, 402-411.	2.5	100
153	Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Letters, 1999, 448, 9-14.	2.8	67
154	Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. British Journal of Cancer, 1999, 79, 1828-1835.	6.4	313
155	Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkinâ€™s Lymphomas. Blood, 1999, 94, 2080-2089.	1.4	12
156	High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. Journal of Neuro-Oncology, 1998, 36, 21-29.	2.9	58
157	Matrix metalloproteinases and diseases of the CNS. Trends in Neurosciences, 1998, 21, 75-80.	8.6	614
158	Altered Balance Between Matrix Metalloproteinases and Their Inhibitors in Experimental Biliary Fibrosis. American Journal of Pathology, 1998, 153, 1895-1902.	3.8	177
159	Oncostatin M Stimulates c-Fos to Bind a Transcriptionally Responsive AP-1 Element within the Tissue Inhibitor of Metalloproteinase-1 Promoter. Journal of Biological Chemistry, 1998, 273, 5211-5218.	3.4	68
160	Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochemical Journal, 1997, 324, 611-617.	3.7	121
161	Murine tissue inhibitor of metalloproteinasesâ€”4 (Timpâ€”4): cDNA isolation and expression in adult mouse tissues¹. FEBS Letters, 1997, 401, 213-217.	2.8	167
162	Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neuroscience Letters, 1997, 238, 53-56.	2.1	296

#	Article	IF	Citations
163	Biology and genetics of implantation. , 1997, 21, 1-5.		2
164	Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. , 1997, 21, 44-54.		139
165	Matrix metalloproteinase-9 maps to the distal end of chromosome 2 in the mouse. , 1997, 21, 55-60.		5
166	Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the periâ€implantation period. Genesis, 1997, 21, 44-54.	2.1	2
167	Tissue inhibitor of metalloproteinases-3 is the major metalloproteinase inhibitor in the decidualizing murine uterus. Molecular Reproduction and Development, 1996, 45, 458-465.	2.0	64
168	Differential effects of transforming growth factor-Î²1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Experimental Gerontology, 1996, 31, 207-223.	2.8	99
169	Temporal and Spatial Expression of Tissue Inhibitors of Metalloproteinases during the Natural Ovulatory Cycle of the Mouse1. Biology of Reproduction, 1996, 55, 498-508.	2.7	58
170	Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. British Journal of Cancer, 1996, 73, 1401-1408.	6.4	118
171	Tissue inhibitor of metalloproteinasesâ€3 is the major metalloproteinase inhibitor in the decidualizing murine uterus. Molecular Reproduction and Development, 1996, 45, 458-465.	2.0	1
172	Endocrinology and paracrinology: Roles of growth factors during peri-implantation development. Human Reproduction, 1995, 10, 712-718.	0.9	89
173	Expression and Activity of Ovarian Tissue Inhibitors of Metalloproteinases during Pseudopregnancy in the Rat1. Biology of Reproduction, 1995, 53, 684-691.	2.7	51
174	Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Letters, 1995, 357, 33-36.	2.8	25
175	Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncology Reports, 1994, 20, 1561.	2.6	34
176	Cell signalling and the control of gene transcription. Trends in Pharmacological Sciences, 1994, 15, 239-244.	8.7	85
177	Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology, 1993, 18, 1437-1442.	7.3	86
178	Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functions. , 1993, 59, 329-341.		241
179	Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology, 1993, 18, 1437-1442.	7.3	8
180	Differential regulation of TIMP-1 and TIMP-2 mRNA expression in normal and Ha-ras-transformed murine fibroblasts. Gene, 1992, 117, 209-217.	2.2	96

#	Article	IF	Citations
181	Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. British Journal of Cancer, 1992, 66, 1188-1194.	6.4	131
182	Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1171, 41-55.	2.4	108
183	Spontaneous immortalization of mouse embryo cells: Strain differences and changes in gene expression with particular reference to retroviral gag-pol genes. Experimental Cell Research, 1991, 192, 128-136.	2.6	17
184	Signalling and superinduction. Nature, 1991, 349, 747-748.	27.8	177
185	Hormonal Regulation of Matrix Metalloproteinase Inhibitors in Rat Granulosa Cells and Ovaries*. Endocrinology, 1991, 128, 1825-1832.	2.8	88
186	Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations.. Genes and Development, 1990, 4, 2308-2318.	5.9	119
187	Differential screening of a cDNA library with cDNA probes amplified in a heterologous host: isolation of murine GRP78 (BiP) and other serum-regulated low-abundance mRNAs. Gene, 1989, 82, 291-303.	2.2	25
188	Specialized Plasmid Vectors for Cloning cDNA. , 1988, 10, 237-251.		1
189	Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. Journal of Cell Biology, 1988, 106, 441-450.	5.2	515
190	Evidence that post-transcriptional changes in the expression of mitogen regulated protein accompany immortalization of mouse cells. Biochemical and Biophysical Research Communications, 1987, 147, 467-473.	2.1	7
191	Synthesis and stability of nuclear matrix proteins in resting and serum-stimulated swiss 3T3 cells. Journal of Cellular Physiology, 1986, 127, 388-396.	4.1	5
192	Gene expression during the mammalian cell cycle. Biochimica Et Biophysica Acta: Reviews on Cancer, 1986, 865, 83-125.	7.4	74
193	A growth-responsive gene (16C8) in normal mouse fibroblasts homologous to a human collagenase inhibitor with erythroid-potentiating activity: evidence for inducible and constitutive transcripts. Nucleic Acids Research, 1986, 14, 8863-8878.	14.5	154
194	A pBR322-derived Vector for Cloning Blunt-ended cDNA: Its Use to Detect Molecular Clones of Low-abundance mRNAs. DNA and Cell Biology, 1985, 4, 401-408.	5.2	4
195	A study of mitochondrial and nuclear transcription with cloned cDNA probes. Experimental Cell Research, 1985, 157, 127-143.	2.6	70
196	The Tissue Inhibitors of Metalloproteinases (TIMPs): Biology and Regulation. , 0, , 67-84.		7